Entry into a Material Definitive Agreement. On June 30, 2026, INmune Bio Inc. (the Company”) entered into a warrant inducement offer letter agreement (the “Inducement Letter”) and into an amendment to common stock purchase warrant (the “Second Amendment”) with certain holders (the “Holders”) of common stock purchase warrants previously issued by the Company in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the “April 2024 War…

The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.

Entry into a Material Definitive Agreement. On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November…

Entry into a Material Definitive Agreement. On December 22, 2025, INmune Bio Inc. (the “Company”) entered into an amendment (the “Warrant Amendment”) with certain holders of warrants previously issued by the Company in its April 2024 offerings on April 24, 2024 and April 29, 2024, respectively (the “April 2024 Warrants”). The exercise price of an aggregate of 1,348,315 outstanding April 2024 Warrants was (i) reduced to $1.95, which price is greater than Minimum Price (as defined in Nasdaq Lis…

Entry into a Material Definitive Agreement. On December 19, 2025, INmune Bio Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through A.G.P., up to $65,000,000 of shares of its common stock, par value $0.001 per share (the “Common Stock”). The Company is not obligated to sell any shares of Common Stock under the Sales Agreement. Subje…

Termination of a Material Definitive Agreement. As previously disclosed, on August 9, 2024, INmune Bio Inc. (the “Company”) entered into an Amended and Restated At-The-Market Sales Agreement (the “Sales Agreement”) with RBC Capital Markets, LLC (“RBC”) and BTIG, LLC (“BTIG”), pursuant to which the Company could offer and sell shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $75,000,000, from time to time through RBC and BTIG…

Material Modification to Rights of Security Holders The information set forth under “

Entry into a Material Definitive Agreement. On December 5, 2025, INmune Bio Inc. (the “Company”) entered into Amendment No. 5 (the “Amendment”) to the Rights Agreement, dated as of December 30, 2020, between the Company and VStock Transfer, LLC, as Rights Agent, as amended (the “Rights Agreement”). The Amendment extended the expiration of the Rights Agreement to December 31, 2026 and provides that such expiration date will automatically extend for successive one-year terms, unless the Company…

Amendments to employment agreements to correct mistakes in base salary and option grants.

President and Chief Executive Officer (Moss), Chief Financial Officer (Ellspermann), Chief Scientific Officer (Lowdell) — David J. Moss, Cory Ellspermann, Mark Lowdell: The company entered into new employment agreements with its key executives, including the CEO, CFO, and Chief Scientific Officer.

The filing describes a stockholders' meeting, not a management change.

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.

Entry into a Material Definitive Agreement. On June 27, 2025, INmune Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two healthcare-focused institutional investors for the sale of an aggregate of 3,000,000 shares of common stock, par value $0.001 per share (the “Shares”), in a registered direct offering (the “Offering”) at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules, for aggregate gross proceeds to the Com…

Other Events. On June 10, 2025, the Company issued a press release announcing the Company’s collaboration with Kirsty Dixon PhD, Assoc Prof. of Surgery at Virginia Commonwealth University in Richmond, Virginia on the interaction of traumatic brain injury and Alzheimer's disease.

The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.

Changes in Registrant’s Certifying Accountant. (a) Resignation of Independent Registered Public Accounting Firm On November 1, 2024, CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum LLP (“Marcum”). On May 7, 2025, INmune Bio Inc. (the “Company”) dismissed Marcum as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s audit committee approved the dismissal. The audit report of Marcum on the Company’s consolidated fina…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Termination of a Material Definitive Agreement. On February 6, 2025, the Company and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“SVB”) entered into a letter agreement pursuant to which the Company and SVB terminated the Loan and Security Agreement (the “Loan Agreement”) dated as of June 10, 2021, by and between the Company, as borrower, and SVB as administrative agent, collateral agent and lender and SVB Innovation Credit Fund VIII, L.P., as a lender, pursuant to…

Entry into a Material Definitive Agreement. On February 6, 2025, INmune Bio Inc. (the “Company”) and Great Ormond Street Hospital NHS Foundation Trust (“GOSH”) entered into a license agreement (the “License Agreement”) for the exclusive commercial use to clinical trial data associated with the Mission EB study (the “Mission EB study”) investigating the potential of CORDStrom to treat recessive dystrophic epidermolysis bullosa (“RDEB”) in pediatric patients. The Company owns the intellectual p…

Entry into a Material Definitive Agreement. On December 30, 2020, the Board of Directors (the “Board”) of INmune Bio Inc., a Nevada corporation (the “Company”), approved and adopted the Rights Agreement, dated as of December 30, 2020 (the “Rights Agreement”), by and between the Company and VStock Transfer, LLC, as rights agent (the “Rights Agent”). The Company and the Rights Agent entered into Amendment No. 1 to the Rights Agreement (“Amendment No. 1”) on December 20, 2021 to extend the expir…

The filing describes the issuance of stock options to directors and certain officers, which is a routine compensatory arrangement.

Material Modification to Rights of Security Holders The information set forth under “

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.